Target Delivery of a Novel Antitumor Organoplatinum(IV)-Substituted Polyoxometalate Complex for Safer and More Effective Colorectal Cancer Therapy In Vivo.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27309631.
- Also identified by DOI 10.1002/adma.201601778.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An inactive organoplatinum(IV)-substituted polyoxometalate is developed as an efficient and nontoxic prodrug with significant potential for treating human colorectal cancers. Further encapsulation of Pt(IV) -PW11 with DSPE-PEG2000 nanoparticles (NPs) enables targeted delivery and controlled release of inactive prodrug. Such Pt(IV) -PW11 -DSPE-PEG2000 NPs are highly efficient in inhibiting cellular growth of HT29 cells and treating human colorectal cancer in mice, superior to classic cisplatin.
Medical subject headings
- Colorectal Neoplasms